Clene Swings to Q3 Net Profit of $3.92 Million

Bitget2026/11/04 13:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Clene swung to third-quarter 2026 net income of $3.92 million from a year-earlier net loss of $8.78 million.
Other income, net, swung to $10.26 million, primarily due to fair-value changes in common stock warrant liabilities and derivative liabilities.
Cash and cash equivalents totaled $9.89 million at September 30, with operating runway expected through mid-first quarter 2027.
An October 2026 FDA submission seeks accelerated approval of CNM-Au8 for amyotrophic lateral sclerosis.
The Phase 3 RESTORE-ALS confirmatory trial is planned to begin randomizing participants in the second quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040830PRIMZONEFULLFEED9869628) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Clene Swings to Q3 Net Profit of $3.92 Million

You may also like

Crypto prices